Taher Darreh-Shori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Taher Darreh-Shori has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
- Agneta Nordberg
Department of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden
22 shared publications - Ove Almkvist
Division of Clinical Geriatrics, Department of Neurobiology Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
10 shared publications - Rajnish Kumar
Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology, Banaras Hindu University, Varanasi-221005, Uttar Pradesh, India
9 shared publications Bengt Långström
Department of Chemistry, Uppsala University, Uppsala, Sweden
7 shared publicationsSwetha Vijayaraghavan
Division of Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
7 shared publications- Amit Kumar
Division of Clinical Geriatrics Center for Alzheimer Research Department of Neurobiology Care Sciences and Society Karolinska Institutet Stockholm Sweden
6 shared publications
Latest Publications
- Open Access
- 13 November 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1694610
From heart to brain: cognitive potential of propranolol and diltiazem through cholinergic enhancement via butyrylcholinesterase inhibition
Background: Butyrylcholinesterase (BChE) has emerged as a promising therapeutic target in the treatment of Alzheimer’s disease (AD), particularly in its later stages when acetylcholinesterase (AChE) activity declines. Drug repurposing offers a strategic approach to identify novel BChE inhibitors among existing FDA-approved compounds. Objective: This study aimed to evaluate the cholinesterase inhibitory potential of propranolol and diltiazem—two widely used cardiovascular drugs—through in silico modelling and in vitro and ex vivo enzyme-inhibition kinetic. Methods: Molecular docking was performed using AutoDock Vina to assess the binding affinity of propranolol and diltiazem to AChE and BChE. In vitro screening and inhibition were measured using a modified Ellman’s assay with human recombinant AChE and plasma-derived BChE. Ex-vivo IC 50 and K i values were determined through kinetic analyses in pooled plasma samples, and inhibition modes were characterized using nonlinear regression models. Results: Both propranolol and diltiazem selectively inhibited BChE, with minimal activity against AChE. At 100 μM, BChE inhibition exceeded 80% for both compounds, while AChE inhibition was limited to 18% (propranolol) and 2% (diltiazem). Propranolol exhibited a K i of 0.19 µM, comparable to the selective BChE inhibitor ethopropazine (K i = 0.15 µM), and acted as a competitive inhibitor. Diltiazem exhibited a higher K i of 2.3 µM. These effects were observed at concentrations within or near reported brain levels for propranolol, suggesting potential in vivo relevance. Conclusion: Propranolol and diltiazem demonstrate selective BChE inhibition, with propranolol showing potency comparable to established potent BChE inhibitors. Given their established safety profiles and CNS activity, these compounds represent promising candidates for repurposing in the treatment of AD and other cognitive disorders. Further in vivo studies are warranted to explore their therapeutic potential.
- 13 November 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1694610
Open AccessFrom heart to brain: cognitive potential of propranolol and diltiazem through cholinergic enhancement via butyrylcholinesterase inhibition
Background: Butyrylcholinesterase (BChE) has emerged as a promising therapeutic target in the treatment of Alzheimer’s disease (AD), particularly in its later stages when acetylcholinesterase (AChE) activity declines. Drug repurposing offers a strategic approach to identify novel BChE inhibitors among existing FDA-approved compounds. Objective: This study aimed to evaluate the cholinesterase inhibitory potential of propranolol and diltiazem—two widely used cardiovascular drugs—through in silico modelling and in vitro and ex vivo enzyme-inhibition kinetic. Methods: Molecular docking was performed using AutoDock Vina to assess the binding affinity of propranolol and diltiazem to AChE and BChE. In vitro screening and inhibition were measured using a modified Ellman’s assay with human recombinant AChE and plasma-derived BChE. Ex-vivo IC 50 and K i values were determined through kinetic analyses in pooled plasma samples, and inhibition modes were characterized using nonlinear regression models. Results: Both propranolol and diltiazem selectively inhibited BChE, with minimal activity against AChE. At 100 μM, BChE inhibition exceeded 80% for both compounds, while AChE inhibition was limited to 18% (propranolol) and 2% (diltiazem). Propranolol exhibited a K i of 0.19 µM, comparable to the selective BChE inhibitor ethopropazine (K i = 0.15 µM), and acted as a competitive inhibitor. Diltiazem exhibited a higher K i of 2.3 µM. These effects were observed at concentrations within or near reported brain levels for propranolol, suggesting potential in vivo relevance. Conclusion: Propranolol and diltiazem demonstrate selective BChE inhibition, with propranolol showing potency comparable to established potent BChE inhibitors. Given their established safety profiles and CNS activity, these compounds represent promising candidates for repurposing in the treatment of AD and other cognitive disorders. Further in vivo studies are warranted to explore their therapeutic potential.
- Open Access
- 23 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10311
Comparative Analysis of Cholinergic Machinery in Carcinomas: Discovery of Membrane-Tethered ChAT as Evidence for Surface-Based ACh Synthesis in Neuroblastoma Cells
The cholinergic system is one of the most ancient and widespread signaling systems in the body, implicated in a range of pathological conditions—from neurodegenerative disorders to cancer. Given its broad relevance, there is growing interest in characterizing this system across diverse cellular models to enable drug screening, mechanistic studies, and exploration of new therapeutic avenues. In this study, we investigated four cancer cell lines: one of neuroblastoma origin previously used in cholinergic signaling studies (SH-SY5Y), one non-small cell lung adenocarcinoma line (A549), and two small cell lung carcinoma lines (H69 and H82). We assessed the expression and localization of key components of the cholinergic system, along with the cellular capacity for acetylcholine (ACh) synthesis and release. Whole-cell flow cytometry following membrane permeabilization revealed that all cell lines expressed the ACh-synthesizing enzyme choline acetyltransferase (ChAT). HPLC-MS analysis confirmed that ChAT was functionally active, as all cell lines synthesized and released ACh into the conditioned media, suggesting the presence of autocrine and/or paracrine ACh signaling circuits, consistent with previous reports. The cell lines also demonstrated choline uptake, indicative of functional choline and/or organic cation transporters. Additionally, all lines expressed the ACh-degrading enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), as well as the alfa seven (α7) nicotinic and M1 muscarinic ACh receptor subtypes. Notably, flow cytometry of intact SH-SY5Y cells revealed two novel findings: (1) ChAT was localized to the extracellular membrane, a feature not observed in the lung cancer cell lines, and (2) BChE, rather than AChE, was the predominant membrane-bound ACh-degrading enzyme. These results were corroborated by both whole-cell and surface-confocal microscopy. In conclusion, our findings suggest that a functional cholinergic phenotype is a shared feature of several carcinoma cell lines, potentially serving as a survival checkpoint that could be therapeutically explored. The discovery of extracellular membrane-bound ChAT uniquely in neuroblastoma SH-SY5Y cells points to a novel form of in situ ACh signaling that warrants further investigation.
- 23 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10311
Open AccessComparative Analysis of Cholinergic Machinery in Carcinomas: Discovery of Membrane-Tethered ChAT as Evidence for Surface-Based ACh Synthesis in Neuroblastoma Cells
The cholinergic system is one of the most ancient and widespread signaling systems in the body, implicated in a range of pathological conditions—from neurodegenerative disorders to cancer. Given its broad relevance, there is growing interest in characterizing this system across diverse cellular models to enable drug screening, mechanistic studies, and exploration of new therapeutic avenues. In this study, we investigated four cancer cell lines: one of neuroblastoma origin previously used in cholinergic signaling studies (SH-SY5Y), one non-small cell lung adenocarcinoma line (A549), and two small cell lung carcinoma lines (H69 and H82). We assessed the expression and localization of key components of the cholinergic system, along with the cellular capacity for acetylcholine (ACh) synthesis and release. Whole-cell flow cytometry following membrane permeabilization revealed that all cell lines expressed the ACh-synthesizing enzyme choline acetyltransferase (ChAT). HPLC-MS analysis confirmed that ChAT was functionally active, as all cell lines synthesized and released ACh into the conditioned media, suggesting the presence of autocrine and/or paracrine ACh signaling circuits, consistent with previous reports. The cell lines also demonstrated choline uptake, indicative of functional choline and/or organic cation transporters. Additionally, all lines expressed the ACh-degrading enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), as well as the alfa seven (α7) nicotinic and M1 muscarinic ACh receptor subtypes. Notably, flow cytometry of intact SH-SY5Y cells revealed two novel findings: (1) ChAT was localized to the extracellular membrane, a feature not observed in the lung cancer cell lines, and (2) BChE, rather than AChE, was the predominant membrane-bound ACh-degrading enzyme. These results were corroborated by both whole-cell and surface-confocal microscopy. In conclusion, our findings suggest that a functional cholinergic phenotype is a shared feature of several carcinoma cell lines, potentially serving as a survival checkpoint that could be therapeutically explored. The discovery of extracellular membrane-bound ChAT uniquely in neuroblastoma SH-SY5Y cells points to a novel form of in situ ACh signaling that warrants further investigation.
- Open Access
- 28 May 2025
- Published by MDPI AG in Preprints.org
Comparative Analysis of Cholinergic Machinery in Carcinomas: Discovery of Membrane‐Tethered ChAT as Evidence for Surface‐Based ACh Synthesis in Neuroblastoma Cells
The cholinergic system is one of the most ancient and widespread signaling systems in the body and is implicated in a variety of pathological conditions, ranging from neuro-degenerative disorders to cancer. Given its broad relevance, there is a growing interest in characterizing this system in diverse cellular models, allowing drug screening and mechanistic studies and assessing further therapeutic avenues. In this work, we investigated four cancer cell lines of neuroblastoma (SH-SY5Y), a lung cancer origin (lung adenocarcinoma line, A549, and two small cell lung carcinoma lines (H69 and H82) for the expression and localization of key components of the cholinergic system, along with their capacity for acetylcholine (ACh) synthesis and release. Whole-cell flow cytometry following membrane permeabilization revealed that all cell lines expressed the ACh-synthesizing enzyme choline acetyltransferase (ChAT). HPLC-MS analysis con-firmed that ChAT was functionally active, as all cell lines synthesized and released ACh into the conditioned media, suggesting the presence of autocrine and/or paracrine ACh signaling circuits in line with previous reports. All cell lines also demonstrated choline uptake, indicative of functional choline and/or organic cation transporters. Additionally, they expressed the ACh-degrading enzymes acetylcholinesterase (AChE) and butyryl-cholinesterase (BChE), along with the nicotinic α7 and muscarinic M1 ACh receptor subtypes. Unexpectedly, flow cytometry of intact SH-SY5Y cells revealed two novel findings: (1) ChAT was localized to the extracellular membrane, which was not evident in the lung cancer cell lines, and (2) BChE, rather than AChE, was the primary mem-brane-bound ACh-degrading enzyme. These results were corroborated by whole-cell and surface-confocal microscopy. In conclusion, our findings suggest that a functional cholinergic phenotype is a shared feature of several carcinoma cell lines, potentially serving as a survival checkpoint. The discovery of extracellular membrane-bound ChAT uniquely in neuroblastoma SH-SY5Y cells points to a novel form of in situ ACh signaling that warrants further investigation.
- 28 May 2025
- Published by MDPI AG in Preprints.org
Open AccessComparative Analysis of Cholinergic Machinery in Carcinomas: Discovery of Membrane‐Tethered ChAT as Evidence for Surface‐Based ACh Synthesis in Neuroblastoma Cells
The cholinergic system is one of the most ancient and widespread signaling systems in the body and is implicated in a variety of pathological conditions, ranging from neuro-degenerative disorders to cancer. Given its broad relevance, there is a growing interest in characterizing this system in diverse cellular models, allowing drug screening and mechanistic studies and assessing further therapeutic avenues. In this work, we investigated four cancer cell lines of neuroblastoma (SH-SY5Y), a lung cancer origin (lung adenocarcinoma line, A549, and two small cell lung carcinoma lines (H69 and H82) for the expression and localization of key components of the cholinergic system, along with their capacity for acetylcholine (ACh) synthesis and release. Whole-cell flow cytometry following membrane permeabilization revealed that all cell lines expressed the ACh-synthesizing enzyme choline acetyltransferase (ChAT). HPLC-MS analysis con-firmed that ChAT was functionally active, as all cell lines synthesized and released ACh into the conditioned media, suggesting the presence of autocrine and/or paracrine ACh signaling circuits in line with previous reports. All cell lines also demonstrated choline uptake, indicative of functional choline and/or organic cation transporters. Additionally, they expressed the ACh-degrading enzymes acetylcholinesterase (AChE) and butyryl-cholinesterase (BChE), along with the nicotinic α7 and muscarinic M1 ACh receptor subtypes. Unexpectedly, flow cytometry of intact SH-SY5Y cells revealed two novel findings: (1) ChAT was localized to the extracellular membrane, which was not evident in the lung cancer cell lines, and (2) BChE, rather than AChE, was the primary mem-brane-bound ACh-degrading enzyme. These results were corroborated by whole-cell and surface-confocal microscopy. In conclusion, our findings suggest that a functional cholinergic phenotype is a shared feature of several carcinoma cell lines, potentially serving as a survival checkpoint. The discovery of extracellular membrane-bound ChAT uniquely in neuroblastoma SH-SY5Y cells points to a novel form of in situ ACh signaling that warrants further investigation.
- Open Access
- 19 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13602
Micellar Choline-Acetyltransferase Complexes Exhibit Ultra-Boosted Catalytic Rate for Acetylcholine Synthesis—Mechanistic Insights for Development of Acetylcholine-Enhancing Micellar Nanotherapeutics
Choline-acetyltransferase (ChAT) is the key cholinergic enzyme responsible for the biosynthesis of acetylcholine (ACh), a crucial signaling molecule with both canonical neurotransmitter function and auto- and paracrine signaling activity in non-neuronal cells, such as lymphocytes and astroglia. Cholinergic dysfunction is linked to both neurodegenerative and inflammatory diseases. In this study, we investigated a serendipitous observation, namely that the catalytic rate of human recombinant ChAT (rhChAT) protein greatly differed in buffered solution in the presence and absence of Triton X-100 (TX100). At a single concentration of 0.05% (v/v), TX100 boosted the specific activity of rhChAT by 4-fold. Dose–response analysis within a TX100 concentration range of 0.8% to 0.008% (accounting for 13.7 mM to 0.013 mM) resulted in an S-shaped response curve, indicative of an over 10-fold boost in the catalytic rate of rhChAT. This dramatic boost was unlikely due to a mere structural stabilization since it remained even after the addition of 1.0 mg/mL gelatin to the ChAT solution as a protein stabilizer. Furthermore, we found that the catalytic function of the ACh-degrading enzyme, AChE, was unaffected by TX100, underscoring the specificity of the effect for ChAT. Examination of the dose–response curve in relation to the critical micelle concentration (CMC) of TX100 revealed that a boost in ChAT activity occurred when the TX100 concentration passed its CMC, indicating that formation of micelle–ChAT complexes was crucial. We challenged this hypothesis by repeating the experiment on Tween 20 (TW20), another non-ionic surfactant with ~3-fold lower CMC compared to TX100 (0.06 vs. 0.2 mM). The analysis confirmed that micelle formation is crucial for ultra-boosting the activity of ChAT. In silico molecular dynamic simulation supported the notion of ChAT–micelle complex formation. We hypothesize that TX100 or TW20 micelles, by mimicking cell–membrane microenvironments, facilitate ChAT in accessing its full catalytic potential by fine-tuning its structural stabilization and/or enhancing its substrate accessibility. These insights are expected to facilitate research toward the development of new cholinergic-enhancing therapeutics through the formulation of micelle-embedded ChAT nanoparticles.
- 19 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13602
Open AccessMicellar Choline-Acetyltransferase Complexes Exhibit Ultra-Boosted Catalytic Rate for Acetylcholine Synthesis—Mechanistic Insights for Development of Acetylcholine-Enhancing Micellar Nanotherapeutics
Choline-acetyltransferase (ChAT) is the key cholinergic enzyme responsible for the biosynthesis of acetylcholine (ACh), a crucial signaling molecule with both canonical neurotransmitter function and auto- and paracrine signaling activity in non-neuronal cells, such as lymphocytes and astroglia. Cholinergic dysfunction is linked to both neurodegenerative and inflammatory diseases. In this study, we investigated a serendipitous observation, namely that the catalytic rate of human recombinant ChAT (rhChAT) protein greatly differed in buffered solution in the presence and absence of Triton X-100 (TX100). At a single concentration of 0.05% (v/v), TX100 boosted the specific activity of rhChAT by 4-fold. Dose–response analysis within a TX100 concentration range of 0.8% to 0.008% (accounting for 13.7 mM to 0.013 mM) resulted in an S-shaped response curve, indicative of an over 10-fold boost in the catalytic rate of rhChAT. This dramatic boost was unlikely due to a mere structural stabilization since it remained even after the addition of 1.0 mg/mL gelatin to the ChAT solution as a protein stabilizer. Furthermore, we found that the catalytic function of the ACh-degrading enzyme, AChE, was unaffected by TX100, underscoring the specificity of the effect for ChAT. Examination of the dose–response curve in relation to the critical micelle concentration (CMC) of TX100 revealed that a boost in ChAT activity occurred when the TX100 concentration passed its CMC, indicating that formation of micelle–ChAT complexes was crucial. We challenged this hypothesis by repeating the experiment on Tween 20 (TW20), another non-ionic surfactant with ~3-fold lower CMC compared to TX100 (0.06 vs. 0.2 mM). The analysis confirmed that micelle formation is crucial for ultra-boosting the activity of ChAT. In silico molecular dynamic simulation supported the notion of ChAT–micelle complex formation. We hypothesize that TX100 or TW20 micelles, by mimicking cell–membrane microenvironments, facilitate ChAT in accessing its full catalytic potential by fine-tuning its structural stabilization and/or enhancing its substrate accessibility. These insights are expected to facilitate research toward the development of new cholinergic-enhancing therapeutics through the formulation of micelle-embedded ChAT nanoparticles.
- Open Access
- 25 November 2024
- Published by MDPI AG in Preprints.org
Micellar-Choline-Acetyltransferase Complexes Exhibit Ultra-Boosted Catalytic Rate for Acetylcholine Synthesis – Mechanistic Insights for Development of Acetylcholine-Enhancing Micellar Nanotherapeutics
Choline acetyltransferase (ChAT) is the key cholinergic enzyme, responsible for biosynthesis of acetylcholine (ACh), a crucial signaling molecule with both canonical neurotransmitter function and the auto- and paracrine signaling activity in non-neuronal cells, like lymphocytes and astroglia. Cholinergic dysfunction is linked to both neurodegenerative and inflammatory diseases. In this study we investigated a serendipitous observation, namely that catalytic rate of human recombinant ChAT (rhChAT) protein greatly differed in buffered solution in presence and absence of Triton X-100 (TX100). At single concentration of 0.05%(v/v), TX100 boosted the specific activity of rhChAT by 4-folds. Dose-response analysis within a TX100 concentration range of 0.8% to 0.008% (accounting for 13.7mM to 0.013mM) resulted in an S-shaped response-curve, indicative of over 10-folds boost in catalytic rate of rhChAT. This dramatic boost was unlikely due to a mere structural stabilization since it remained even after addition of 1.0 mg/mL gelatin to the ChAT solution as a protein stabilizer. Furthermore, we found that the catalytic function of the ACh-degrading enzyme, AChE, was unaffected by TX100, underscoring specificity of the effect for ChAT. Examination of the dose-response curve in relation to the critical micelle concentration (CMC) of TX100 revealed that the boost in ChAT activity occurred when the TX100 concentration passed its CMC, indicating that formation of micelle-ChAT complexes was crucial. We challenged this hypothesis by repeating the experiment on Tween-20 (TW20), another non-ionic surfactant with ~3-folds lower CMC compared to TX100 (0.06 vs 0.2mM). The analysis confirmed that micelle formation is crucial for ultra-boosting the activity of ChAT. In-silico molecular dynamic simulation supported the notion of ChAT-micelle complex formation. We hypothesize that TX100 or TW20 micelles, by mimicking cell-membrane microenvironments, facilitate ChAT in accessing its full catalytic potential by fine-tuning its structural stabilization and/or enhancing its substrate accessibility. These insights is expected to facilitate research toward development of new cholinergic-enhancing therapeutics through formulation of micelle-embedded ChAT nanoparticle.
- 25 November 2024
- Published by MDPI AG in Preprints.org
Open AccessMicellar-Choline-Acetyltransferase Complexes Exhibit Ultra-Boosted Catalytic Rate for Acetylcholine Synthesis – Mechanistic Insights for Development of Acetylcholine-Enhancing Micellar Nanotherapeutics
Choline acetyltransferase (ChAT) is the key cholinergic enzyme, responsible for biosynthesis of acetylcholine (ACh), a crucial signaling molecule with both canonical neurotransmitter function and the auto- and paracrine signaling activity in non-neuronal cells, like lymphocytes and astroglia. Cholinergic dysfunction is linked to both neurodegenerative and inflammatory diseases. In this study we investigated a serendipitous observation, namely that catalytic rate of human recombinant ChAT (rhChAT) protein greatly differed in buffered solution in presence and absence of Triton X-100 (TX100). At single concentration of 0.05%(v/v), TX100 boosted the specific activity of rhChAT by 4-folds. Dose-response analysis within a TX100 concentration range of 0.8% to 0.008% (accounting for 13.7mM to 0.013mM) resulted in an S-shaped response-curve, indicative of over 10-folds boost in catalytic rate of rhChAT. This dramatic boost was unlikely due to a mere structural stabilization since it remained even after addition of 1.0 mg/mL gelatin to the ChAT solution as a protein stabilizer. Furthermore, we found that the catalytic function of the ACh-degrading enzyme, AChE, was unaffected by TX100, underscoring specificity of the effect for ChAT. Examination of the dose-response curve in relation to the critical micelle concentration (CMC) of TX100 revealed that the boost in ChAT activity occurred when the TX100 concentration passed its CMC, indicating that formation of micelle-ChAT complexes was crucial. We challenged this hypothesis by repeating the experiment on Tween-20 (TW20), another non-ionic surfactant with ~3-folds lower CMC compared to TX100 (0.06 vs 0.2mM). The analysis confirmed that micelle formation is crucial for ultra-boosting the activity of ChAT. In-silico molecular dynamic simulation supported the notion of ChAT-micelle complex formation. We hypothesize that TX100 or TW20 micelles, by mimicking cell-membrane microenvironments, facilitate ChAT in accessing its full catalytic potential by fine-tuning its structural stabilization and/or enhancing its substrate accessibility. These insights is expected to facilitate research toward development of new cholinergic-enhancing therapeutics through formulation of micelle-embedded ChAT nanoparticle.
- 31 October 2024
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (22) , 4156-4170
AI-Enabled Ultra-large Virtual Screening Identifies Potential Inhibitors of Choline Acetyltransferase for Theranostic Purposes
Alzheimer's disease (AD) and related dementias are among the primary neurological disorders and call for the urgent need for early-stage diagnosis to gain an upper edge in therapeutic intervention and increase the overall success rate. Choline acetyltransferase (ChAT) is the key acetylcholine (ACh) biosynthesizing enzyme and a legitimate target for the development of biomarkers for early-stage diagnosis and monitoring of therapeutic responses. It is also a theranostic target for tackling colon and lung cancers, where overexpression of non-neuronal ChAT leads to the production of acetylcholine, which acts as an autocrine growth factor for cancer cells. Theranostics is a hybrid of diagnostics and therapeutics that can be used to locate cancer cells using radiotracers and kill them without affecting other healthy tissues. Traditional virtual screening protocols have a lot of limitations; given the current rate of chemical database expansion exceeding billions, much faster screening protocols are required. Deep docking (DD) is one such platform that leverages the power of deep neural network (DNN)-based virtual screening, empowering researchers to dock billions of molecules in a speedy, yet explicit manner. Here, we have screened 1.3 billion compounds library from the ZINC20 database, identifying the best-performing hits. With each iteration run where the first iteration gave ∼116 million hits, the second iteration gave ∼3.7 million hits, and the final third iteration gave 168,447 hits from which further refinement gave us the top 5 compounds as potential ChAT inhibitors. The discovery of novel ChAT inhibitors will enable researchers to develop new probes that can be used as novel theranostic agents against cancer and as early-stage diagnostics for the onset of AD, for timely therapeutic intervention to halt the further progression of AD.
- 31 October 2024
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (22) , 4156-4170
AI-Enabled Ultra-large Virtual Screening Identifies Potential Inhibitors of Choline Acetyltransferase for Theranostic Purposes
Alzheimer's disease (AD) and related dementias are among the primary neurological disorders and call for the urgent need for early-stage diagnosis to gain an upper edge in therapeutic intervention and increase the overall success rate. Choline acetyltransferase (ChAT) is the key acetylcholine (ACh) biosynthesizing enzyme and a legitimate target for the development of biomarkers for early-stage diagnosis and monitoring of therapeutic responses. It is also a theranostic target for tackling colon and lung cancers, where overexpression of non-neuronal ChAT leads to the production of acetylcholine, which acts as an autocrine growth factor for cancer cells. Theranostics is a hybrid of diagnostics and therapeutics that can be used to locate cancer cells using radiotracers and kill them without affecting other healthy tissues. Traditional virtual screening protocols have a lot of limitations; given the current rate of chemical database expansion exceeding billions, much faster screening protocols are required. Deep docking (DD) is one such platform that leverages the power of deep neural network (DNN)-based virtual screening, empowering researchers to dock billions of molecules in a speedy, yet explicit manner. Here, we have screened 1.3 billion compounds library from the ZINC20 database, identifying the best-performing hits. With each iteration run where the first iteration gave ∼116 million hits, the second iteration gave ∼3.7 million hits, and the final third iteration gave 168,447 hits from which further refinement gave us the top 5 compounds as potential ChAT inhibitors. The discovery of novel ChAT inhibitors will enable researchers to develop new probes that can be used as novel theranostic agents against cancer and as early-stage diagnostics for the onset of AD, for timely therapeutic intervention to halt the further progression of AD.
- Open Access
Functional Glial Activation Mediates Phenotypic Effects of APOEɛ4 and Sex in Alzheimer’s Disease
Background: This study examined the impact of apolipoprotein ɛ4 (APOEɛ4) allele frequency and sex on the phenotype of Alzheimer’s disease (AD). Methods: This post hoc study evaluated the baseline characteristics, cerebrospinal fluid (CSF) and neuroimaging biomarkers, and cognition scores collected from 45 patients aged 50–74 years with CSF-biomarker-confirmed mild cognitive impairment or mild dementia due to AD from clinical trial NCT03186989. Results: A phenotypic spectrum was observed from a predominant amyloid and limbic–amnestic phenotype in male APOEɛ4 homozygotes to a predominantly tau, limbic-sparing, and multidomain cognitive impairment phenotype in female APOEɛ4 noncarriers. Amyloid pathology was inversely correlated with tau pathophysiology, glial activation, and synaptic injury, with the strongest associations observed in male APOEɛ4 carriers. Tau pathophysiology was correlated with glial activation, synaptic injury, and neuroaxonal damage, with the strongest correlation observed in female APOEɛ4 noncarriers. Conclusions: These data support the hypothesis that functional glial activation is influenced by apoE isoform and sex and might explain much of the biological and clinical heterogeneity in early clinical AD in those aged 50–74 years. Conclusions are limited because of the retrospective nature and small sample size. Trial Registration: Clinical Trial NCT03186989.
Open AccessFunctional Glial Activation Mediates Phenotypic Effects of APOEɛ4 and Sex in Alzheimer’s Disease
Background: This study examined the impact of apolipoprotein ɛ4 (APOEɛ4) allele frequency and sex on the phenotype of Alzheimer’s disease (AD). Methods: This post hoc study evaluated the baseline characteristics, cerebrospinal fluid (CSF) and neuroimaging biomarkers, and cognition scores collected from 45 patients aged 50–74 years with CSF-biomarker-confirmed mild cognitive impairment or mild dementia due to AD from clinical trial NCT03186989. Results: A phenotypic spectrum was observed from a predominant amyloid and limbic–amnestic phenotype in male APOEɛ4 homozygotes to a predominantly tau, limbic-sparing, and multidomain cognitive impairment phenotype in female APOEɛ4 noncarriers. Amyloid pathology was inversely correlated with tau pathophysiology, glial activation, and synaptic injury, with the strongest associations observed in male APOEɛ4 carriers. Tau pathophysiology was correlated with glial activation, synaptic injury, and neuroaxonal damage, with the strongest correlation observed in female APOEɛ4 noncarriers. Conclusions: These data support the hypothesis that functional glial activation is influenced by apoE isoform and sex and might explain much of the biological and clinical heterogeneity in early clinical AD in those aged 50–74 years. Conclusions are limited because of the retrospective nature and small sample size. Trial Registration: Clinical Trial NCT03186989.
- Open Access
- 21 August 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (35) , 37299-37309
Repurposing Duloxetine as a Potent Butyrylcholinesterase Inhibitor: Potential Cholinergic Enhancing Benefits for Elderly Individuals with Depression and Cognitive Impairment
Despite the advent of new treatment strategies, cholinesterase inhibitors (ChEIs) are still the go-to treatment for dementia disorders. ChEIs act by inhibiting the main acetylcholine-degrading enzyme, acetylcholinesterase (AChE). Nonetheless, accumulating evidence indicates that the impact of inhibition of the sister enzyme, butyrylcholinesterase (BChE), could be even broader in older adults due to the multifaceted role of BChE in several biological functional pathways. Therefore, we employed an in silico modeling-based drug repurposing strategy to identify novel potent BChE inhibitors from the FDA drug database. This was followed by in vitro screening and ex vivo enzyme kinetic validation using human plasma samples as the source of BChE. The analysis revealed that the antidepressant drug, duloxetine, inhibited BChE with high selectivity in comparison to AChE. In contrast, two other antidepressants, namely, citalopram and escitalopram exhibited a weak to moderate activity. Ex vivo enzyme inhibition kinetic analyses indicated that duloxetine acted as a competitive inhibitor of BChE with an inhibition constant (K-i) of 210 nM. This K-i value is comparable with 100-400 nM concentration of duloxetine following normal dosages in humans, thereby indicating that duloxetine should be able to induce a pharmacologically and biologically relevant in vivo inhibition of BChE. Additionally, we performed the enzyme inhibition kinetic assessment in parallel for ethopropazine, a known potent selective BChE inhibitor, and physostigmine, a dual inhibitor of AChE and BChE. These analyses indicated that duloxetine should be considered a potent BChE inhibitor since its K-i was comparable with ethopropazine (K-i = 150 nM) but was 4 times smaller than that of physostigmine (K-i= 840 nM). In conclusion, this study reports the discovery of duloxetine being a highly potent selective competitive BChE inhibitor. This, in turn, indicates that duloxetine could be the choice of antidepressive treatment in older adults with both depressive and dementia symptoms since it may offer additional clinically beneficial effects via this secondary mode of cholinergic enhancing action.
- 21 August 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (35) , 37299-37309
Open AccessRepurposing Duloxetine as a Potent Butyrylcholinesterase Inhibitor: Potential Cholinergic Enhancing Benefits for Elderly Individuals with Depression and Cognitive Impairment
Despite the advent of new treatment strategies, cholinesterase inhibitors (ChEIs) are still the go-to treatment for dementia disorders. ChEIs act by inhibiting the main acetylcholine-degrading enzyme, acetylcholinesterase (AChE). Nonetheless, accumulating evidence indicates that the impact of inhibition of the sister enzyme, butyrylcholinesterase (BChE), could be even broader in older adults due to the multifaceted role of BChE in several biological functional pathways. Therefore, we employed an in silico modeling-based drug repurposing strategy to identify novel potent BChE inhibitors from the FDA drug database. This was followed by in vitro screening and ex vivo enzyme kinetic validation using human plasma samples as the source of BChE. The analysis revealed that the antidepressant drug, duloxetine, inhibited BChE with high selectivity in comparison to AChE. In contrast, two other antidepressants, namely, citalopram and escitalopram exhibited a weak to moderate activity. Ex vivo enzyme inhibition kinetic analyses indicated that duloxetine acted as a competitive inhibitor of BChE with an inhibition constant (K-i) of 210 nM. This K-i value is comparable with 100-400 nM concentration of duloxetine following normal dosages in humans, thereby indicating that duloxetine should be able to induce a pharmacologically and biologically relevant in vivo inhibition of BChE. Additionally, we performed the enzyme inhibition kinetic assessment in parallel for ethopropazine, a known potent selective BChE inhibitor, and physostigmine, a dual inhibitor of AChE and BChE. These analyses indicated that duloxetine should be considered a potent BChE inhibitor since its K-i was comparable with ethopropazine (K-i = 150 nM) but was 4 times smaller than that of physostigmine (K-i= 840 nM). In conclusion, this study reports the discovery of duloxetine being a highly potent selective competitive BChE inhibitor. This, in turn, indicates that duloxetine could be the choice of antidepressive treatment in older adults with both depressive and dementia symptoms since it may offer additional clinically beneficial effects via this secondary mode of cholinergic enhancing action.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Cholinergic pathway modulation by age‐dependent amyloid‐beta pathology in an APP‐knock‐in AD mice model
Background: Altered cholinergic pathways and memory dysfunction are well‐known changes during Alzheimer’s disease (AD), linked to the early loss of basal forebrain cholinergic neurons (BFCNs). BFCN’s innervates wide regions of the brain, including hippocampus which is a crucial site of neurotrophic factor production like nerve growth factor (NGF) – the master regulator of cholinergic pathways and brain derived neurotrophic factor (BDNF). Hippocampus coordinates memory and cognition and is found affected with amyloid‐beta (Aβ) pathology in AD. Till date, a clear connection between Aβ pathology in modulating cholinergic alteration has not been proven. Recently, the anti‐amyloid antibody Aducanumab and Lecanemab was approved for AD therapy by the United States of America Food and Drug Administration but whether Aβ deposition or clearance modulates cholinergic activity is not established. We evaluated cholinergic status in hippocampus of AD mice model in‐comparison with matched wildtype control.Method: Hippocampus tissue was isolated from a humanized APP‐knock‐in mouse model of AD (AppNL‐G‐F) at different stages of amyloid pathology – 2‐month age (pre‐plaque stage), 7‐month age (plaques present + initiation of cognitive deficits), and 12‐month age (advanced amyloid pathology), and age‐matched wildtype control (C57BL/6JRj) respectively. Tissues were then processed to isolate total protein which was achieved by extracting them in various buffers (soluble, ionic, and detergent soluble fractions) and pooled together. Enzyme assays for cholinergic markers including acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), choline acetyltransferase (ChAT) was performed, along with ELISA for the estimation of total NGF and BDNF levels, respectively.Result: Age‐dependent changes were observed in AppNL‐G‐F mice compared to wild‐type controls. Cholinesterase activity was increased for AChE at 7 months, while BuChE activity was less in the AppNL‐G‐F mice from 7 month onwards, with respect to wildtype control mice respectively. ChAT levels were nominally affected but the cholinergic index (ChAT/AChE) was considerably altered in AppNL‐G‐F mice. NGF levels remained unchanged, but BDNF levels increased in an age‐dependent manner in AppNL‐G‐F mice as compared to control mice.Conclusion: Significant age‐dependent alteration in cholinergic activity and neurotrophic factors were evident in hippocampus tissue of AppNL‐G‐F mice, when compared to wild‐type counterparts underlining the importance of the cholinergic activity in relation to amyloid pathology.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessCholinergic pathway modulation by age‐dependent amyloid‐beta pathology in an APP‐knock‐in AD mice model
Background: Altered cholinergic pathways and memory dysfunction are well‐known changes during Alzheimer’s disease (AD), linked to the early loss of basal forebrain cholinergic neurons (BFCNs). BFCN’s innervates wide regions of the brain, including hippocampus which is a crucial site of neurotrophic factor production like nerve growth factor (NGF) – the master regulator of cholinergic pathways and brain derived neurotrophic factor (BDNF). Hippocampus coordinates memory and cognition and is found affected with amyloid‐beta (Aβ) pathology in AD. Till date, a clear connection between Aβ pathology in modulating cholinergic alteration has not been proven. Recently, the anti‐amyloid antibody Aducanumab and Lecanemab was approved for AD therapy by the United States of America Food and Drug Administration but whether Aβ deposition or clearance modulates cholinergic activity is not established. We evaluated cholinergic status in hippocampus of AD mice model in‐comparison with matched wildtype control.Method: Hippocampus tissue was isolated from a humanized APP‐knock‐in mouse model of AD (AppNL‐G‐F) at different stages of amyloid pathology – 2‐month age (pre‐plaque stage), 7‐month age (plaques present + initiation of cognitive deficits), and 12‐month age (advanced amyloid pathology), and age‐matched wildtype control (C57BL/6JRj) respectively. Tissues were then processed to isolate total protein which was achieved by extracting them in various buffers (soluble, ionic, and detergent soluble fractions) and pooled together. Enzyme assays for cholinergic markers including acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), choline acetyltransferase (ChAT) was performed, along with ELISA for the estimation of total NGF and BDNF levels, respectively.Result: Age‐dependent changes were observed in AppNL‐G‐F mice compared to wild‐type controls. Cholinesterase activity was increased for AChE at 7 months, while BuChE activity was less in the AppNL‐G‐F mice from 7 month onwards, with respect to wildtype control mice respectively. ChAT levels were nominally affected but the cholinergic index (ChAT/AChE) was considerably altered in AppNL‐G‐F mice. NGF levels remained unchanged, but BDNF levels increased in an age‐dependent manner in AppNL‐G‐F mice as compared to control mice.Conclusion: Significant age‐dependent alteration in cholinergic activity and neurotrophic factors were evident in hippocampus tissue of AppNL‐G‐F mice, when compared to wild‐type counterparts underlining the importance of the cholinergic activity in relation to amyloid pathology.